Common adverse effects in studies were temporary bradycardia (slow heartbeat), usually at the beginning of the treatment, dyspnoea (breathing difficulties), and increased liver enzymes (without symptoms). No significant increase of infections was observed under<unk>  therapy. QT prolongation is detectable but was considered to be too low to be of clinical importance in a study.
Ponesimod
Ozanimod
Siponimod
Fingolimod
Caplacizumab
Sarilumab
Benralizumab
Atezolizumab